

US009339274B2

(12) United States Patent

(10) Patent No.: US 9,339,274 B2 (45) Date of Patent: May 17, 2016

(54) PARAVALVULAR LEAK OCCLUSION DEVICE FOR SELF-EXPANDING HEART VALVES

(71) Applicant: AGA Medical Corporation, Plymouth,

MN (US)

(72) Inventor: Gregory James Dakin, Minneapolis,

MN (US)

(73) Assignee: St. Jude Medical, Cardiology Division,

Inc., St. Paul, MN (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 172 days.

(21) Appl. No.: 13/797,513

(22) Filed: Mar. 12, 2013

(65) **Prior Publication Data**

US 2014/0277425 A1 Sep. 18, 2014

(51) Int. Cl.

A61B 17/08 (2006.01) **A61B 17/12** (2006.01)

(Continued)

(52) U.S. Cl.

CPC A61B 17/12122 (2013.01); A61B 17/12172 (2013.01); A61B 17/12118 (2013.01); A61F 2/2418 (2013.01); A61F 2002/077 (2013.01); A61F 2250/0069 (2013.01)

(58) Field of Classification Search

CPC A61F 2/24; A61F 2/2409; A61F 2/2412; A61F 2/2418; A61F 2/2427; A61F 2/243; A61F 2/2433; A61F 2/2436; A61F 2/2439; A61F 2/246; A61F 2/2436; A61F 2/2439; A61F 2/246; A61F 2002/823; A61F 2/82; A61F 2/86; A61F 2/856; A61F 2/88; A61F 2/89; A61F 2/90; A61F 2/915; A61F 2/02/91508–2002/91591; A61B 17/12122; A61B 17/12022; A61B 17/12136; A61B 17/12109; A61B 17/12113; A61B 17/12136;

(56) References Cited

U.S. PATENT DOCUMENTS

3,657,744 A 4/1972 Ersek 4,275,469 A 6/1981 Gabbay (Continued)

FOREIGN PATENT DOCUMENTS

DE 19857887 A1 7/2000 DE 10121210 A1 11/2002 (Continued)

OTHER PUBLICATIONS

Catheter-implanted prosthetic heart valves, Knudsen, L.L., et al., The International Journal of Artificial Organs, vol. 16, No. 5 1993, pp. 253-262.


(Continued)

Primary Examiner — Jonathan W Miles
Assistant Examiner — Kankindi Rwego
(74) Attorney, Agent, or Firm — Lerner, David, Littenberg,
Krumholz & Mentlik, LLP

(57) ABSTRACT

An occluder for sealing gaps between a medical device and adjacent body tissue includes an expandable body configured to fill the gaps between the medical device and the body tissue. The occluder includes a fastener at one end of the body and adapted to couple to a first end of the medical device, and an expandable disk at the other end of the body and adapted to couple to the medical device at a position spaced from the first end.

20 Claims, 9 Drawing Sheets



US 9,339,274 B2

Page 2

(51) Int CI		7 790 725 D2	8/2010	House at al
(51) Int. Cl.	(2007, 01)	7,780,725 B2 7,799,069 B2		Haug et al. Bailey et al.
A61F 2/24	(2006.01)	7,803,185 B2	9/2010	Gabbay
A61F 2/07	(2013.01)	7,824,442 B2	11/2010	Salahieh et al.
		7,837,727 B2		Goetz et al.
(56) References Cited		7,846,203 B2 7,846,204 B2	12/2010	Cribier Letac et al.
II C DATEN	DOCLIMENTS	7,892,281 B2	2/2010	Seguin et al.
U.S. PATEN	T DOCUMENTS	7,914,569 B2	3/2011	Nguyen et al.
4,491,986 A 1/198	5 Gabbay	7,959,666 B2	6/2011	Salahieh et al.
	8 Gabbay	7,959,672 B2	6/2011	Salahieh et al.
	9 Lindemann et al.	7,972,378 B2 7,988,724 B2	7/2011 8/2011	Tabor et al. Salahieh et al.
	0 Strecker 1 Dobben	7,993,394 B2		Hariton et al.
	5 Andersen et al.	8,016,877 B2	9/2011	Seguin et al.
	5 Boguslaski et al.	D648,854 S	11/2011	
	6 Ravenscroft et al.	8,048,153 B2 8,052,741 B2	11/2011 11/2011	Salahieh et al. Bruszewski et al.
5,843,167 A 12/199	8 Dwyer et al.	8,052,741 B2 8,052,749 B2	11/2011	Salahieh et al.
	8 Kotula et al 606/213 9 Bessler et al.	8,052,750 B2	11/2011	Tuval et al.
	9 Gabbay	8,062,355 B2		Figulla et al.
	9 Nguyen et al.	8,075,611 B2 D652,926 S	12/2011 1/2012	Millwee et al.
	0 Webb	D652,920 S		Braido et al.
	0 Starr et al. 0 Robinson et al.	D653,341 S		Braido et al.
	O Taylor et al.	D653,342 S		Braido et al.
	0 Gabbay	D653,343 S	1/2012 2/2012	Ness et al.
	1 Letendre et al.	D654,169 S D654,170 S		Braido et al.
	1 Gabbay	8,137,398 B2	3/2012	
	1 Letendre et al. 2 Gabbay	8,142,497 B2		Friedman
	2 Gabbay	D660,432 S	5/2012	
	2 Ogle et al.	D660,433 S D660,967 S	5/2012	Braido et al. Braido et al.
	2 Besselink	8,182,528 B2	5/2012	
	3 Gabbay 3 Hankh et al.	8,221,493 B2		Boyle et al.
	3 Gabbay	8,230,717 B2	7/2012	
	3 Gabbay	8,231,670 B2 8,252,051 B2	7/2012 8/2012	
6,623,518 B2 9/200		8,308,798 B2		Pintor et al.
6,652,578 B2 11/200 6,685,625 B2 2/200	3 Bailey et al. 4 Gabbay	8,313,525 B2	11/2012	
	4 Klaco	8,323,335 B2		Rowe et al.
6,719,789 B2 4/200	4 Cox	8,323,336 B2 8,343,213 B2	12/2012 1/2013	Hill et al. Salahieh et al.
	4 Spenser et al.	8,348,995 B2	1/2013	Tuval et al.
	4 Gabbay 4 Beyersdorf et al.	8,348,996 B2	1/2013	Tuval et al.
	4 Thompson et al.	8,348,998 B2	1/2013	Pintor et al.
6,830,584 B1 12/200	4 Seguin	8,366,769 B2	2/2013 3/2013	Huynh et al. Quadri et al.
	5 Gabbay	8,403,983 B2 8,408,214 B2	4/2013	Spenser
	5 Spenser et al. 5 Cribier	8,414,643 B2	4/2013	Tuval et al.
	5 Dilling	8,425,593 B2	4/2013	Braido et al.
	6 Smith 623/1.36	8,449,599 B2 8,449,604 B2		Chau et al. Moaddeb et al.
	6 Seguin et al.	8,454,686 B2		Alkhatib
	6 Gabbay 6 Schreck	8,500,798 B2		Rowe et al.
	7 Gabbay	8,568,474 B2	10/2013	Yeung et al.
7,195,641 B2 3/200	7 Palmaz et al.	8,579,962 B2 8,579,966 B2	11/2013 11/2013	Salahieh et al. Seguin et al.
	7 Gabbay	8,585,755 B2	11/2013	
	7 DiMatteo et al. 7 Spenser et al 623/1.24	8,591,575 B2	11/2013	Cribier
7,311,730 B2 12/200		8,597,349 B2	12/2013	Alkhatib
	8 Lashinski et al.	8,603,159 B2 8,603,160 B2	12/2013 12/2013	Seguin et al. Salahieh et al.
	8 Seguin et al.	8,613,765 B2	12/2013	Bonhoeffer et al.
	8 Gabbay 8 Schreck	8,623,074 B2	1/2014	Ryan
	8 Salahieh et al.	8,652,204 B2	2/2014	
7,452,371 B2 11/200	8 Pavenik et al.	8,663,322 B2		Keranen
	9 Gabbay	8,668,733 B2 8,685,080 B2	3/2014 4/2014	Haug et al. White
7,510,575 B2 3/200 7,524,331 B2 4/200	9 Spenser et al. 9 Birdsall	8,728,154 B2		Alkhatib
	9 Friedman	8,747,459 B2		Nguyen et al.
RE40,816 E 6/200	9 Taylor et al.	8,764,820 B2	7/2014	
7,585,321 B2 9/200		8,795,357 B2		Yohanan et al.
7,628,805 B2 12/200 7,682,390 B2 3/201	9 Spenser et al. 0 Seguin	8,801,776 B2 8,808,356 B2		House et al. Braido et al.
	O Seguin O Rowe et al.	8,808,330 B2 8,828,078 B2	9/2014	
7,731,742 B2 6/201		8,834,563 B2		Righini
7,748,389 B2 7/201		8,840,663 B2		Salahieh et al.

(56)	Referen	ices Cited		86484 A		Hariton et al.	
211	PATENT	DOCUMENTS	2010/004 2010/008			House et al. Lattouf	
0.5	. FAILINI	DOCUMENTS	2010/013			Case et al.	
8,876,894 B2	11/2014	Tuval et al.	2010/016	58778 A	1 7/2010	Braido	
8,876,895 B2		Tuval et al.	2010/016			Braido et al.	
8,940,040 B2		Shahriari		58844 A.		Toomes et al.	
8,945,209 B2		Bonyuet et al.	2010/018 2010/019			Braido et al. Alkhatib	
8,961,595 B2 8,974,523 B2		Alkhatib Thill et al.	2010/010			Alkhatib	
8,974,524 B2		Yeung et al.	2010/020		1 8/2010	Alkhatib	
2002/0036220 A1		Gabbay	2010/021			Chau et al.	
2003/0023303 A1		Palmaz et al.	2010/023				
2003/0050694 A1		Yang et al.	2010/024	19911 A. 19923 A.		Alkhatib Alkhatib et al.	
2003/0130726 A1 2004/0044391 A1		Thorpe et al. Porter 623/1.1		36768 A		Alkhatib	
2004/0049262 A1		Obermiller et al.	2010/029	98931 A		Quadri et al.	
2004/0093075 A1		Kuehne	2011/002			Gabbay	
2004/0111111 A1	6/2004		2011/003	54466 A.		Rothstein et al. Thornton et al.	
2004/0210304 A1		Seguin et al.		98800 A		Braido et al.	
2004/0260389 A1 2005/0096726 A1		Case et al. Sequin et al.	2011/009			Braido et al.	
2005/0137682 A1		Justino		37397 A		Chau et al.	
2005/0137695 A1		Salahieh et al.	2011/013			Nguyen et al.	
2005/0137697 A1		Salahieh et al.	2011/020 2011/020				
2005/0203605 A1		Dolan	2011/020				
2005/0256566 A1 2006/0008497 A1		Gabbay Gabbay	2012/003			Braido et al.	
2006/0074484 A1		Huber	2012/003			Vidlund et al.	
2006/0122692 A1	6/2006	Gilad et al.	2012/010			Kovalsky et al.	
2006/0149360 A1		Schwammenthal et al.	2012/012	23529 A.		Levi et al. Gorman, III et al.	
2006/0161249 A1		Realyvasquez et al.	2012/030			Delaloye et al.	
2006/0173532 A1 2006/0178740 A1		Flagle et al. Stacchino et al.	2014/012			Duffy et al.	
2006/0195181 A1		Johnson et al.	2014/015		1 6/2014	Braido	
2006/0206202 A1	9/2006	Bonhoeffer et al.	2014/021			Vidlund et al.	
2006/0241744 A1	10/2006		2014/022 2014/030			Chau et al. Cox et al.	
2006/0241745 A1	10/2006		2014/030			Gross et al.	
2006/0259120 A1 2006/0259137 A1		Vongphakdy et al. Artof et al.	2014/034			Yohanan et al.	
2006/0265056 A1		Nguyen et al.	2014/035	50668 A		Delaloye et al.	
2006/0276813 A1		Greenberg	2014/035	50669 A	1 11/2014	Gillespie et al.	
2006/0276874 A1		Wilson et al.					
2006/0287717 A1		Rowe et al.		FORE	EIGN PATE	NT DOCUMENTS	
2007/0010876 A1 2007/0027534 A1		Salahieh et al. Bergheim et al.	DE	202008	3009610 U1	12/2008	
2007/0027534 A1		Seguin et al.	EP		009010 01 0850607 A1	7/1998	
2007/0050012 A1		Densford 623/1.23	EP		.000590 A1	5/2000	
2007/0055355 A1		Kim et al 623/1.21	EP		360942 A1	11/2003	
2007/0055358 A1		Krolik et al.	EP		584306 A1	10/2005	
2007/0067029 A1 2007/0093890 A1		Gabbay Eliasen et al.	EP EP		.598031 A2 .537487 A1	11/2005 12/2012	
2007/0100435 A1		Case et al.	FR		2847800 A1	6/2004	
2007/0118210 A1		Pinchuk	FR		2850008 A1	7/2004	
2007/0213813 A1		Von Segesser et al.	WO	9	0117720 A1	11/1991	
2007/0233228 A1		Eberhardt et al.	WO		716133 A1	5/1997	
2007/0244545 A1 2007/0244552 A1		Birdsall et al. Salahieh et al.	WO WO		9832412 A2	7/1998 3/1999	
2007/0288087 A1		Fearnot et al.	WO		913801 A1 0128459 A1	4/2001	
2008/0021552 A1	1/2008	Gabbay	wo		149213 A2	7/2001	
2008/0039934 A1	2/2008		WO	0	154625 A1	8/2001	
2008/0071369 A1		Tuval et al.	WO		0156500 A2	8/2001	
2008/0082164 A1 2008/0097595 A1		Friedman Gabbay	WO WO		0176510 A2	10/2001	
2008/003/353 A1 2008/0114452 A1		Gabbay	WO)236048 A1)247575 A2	5/2002 6/2002	
2008/0125853 A1		Bailey et al.	wo		047468 A1	6/2003	
2008/0140189 A1		Nguyen et al.	WO		5073626 A2	7/2006	
2008/0147183 A1	6/2008		WO		071436 A2	6/2007	
2008/0154355 A1		Benichou et al. Obermiller et al.	WO		8070797 A2	6/2008	
2008/0154356 A1 2008/0243245 A1		Thambar et al.	WO WO		0008548 A2 0008549 A1	1/2010 1/2010	
2008/0255662 A1		Stacchino et al.	WO		006349 A1	8/2010	
2008/0262602 A1		Wilk et al.	WO		098857 A1	9/2010	
2008/0269879 A1		Sathe et al.		,	ЛГНГВ ВІТ	BLICATIONS	
2009/0099653 A1		Suri et al.		,	OTTIER FU.	DLICATIONS	
2009/0112309 A1 2009/0138079 A1	4/2009 5/2009	Jaramillo et al. Tuval et al.	Is It Reaso	nable to	Treat All Calo	cified Stenotic Aortic Valves With a	
2009/0138079 A1 2009/0276027 A1	11/2009		Valved Stent?, 579-584, Zegdi, Rachid, MD, PhD et al., J. of the				
2010/0004740 A1		Seguin et al.				y, vol. 51, No. 5, Feb. 5, 2008.	
		•		·			

(56) References Cited

OTHER PUBLICATIONS

Quaden et al., "Percutaneous aortic valve replacement: resection before implantation", pp. 836-840, European J. of Cardio-thoracic Surgery, 27 (2005).

Ruiz, Carlos, Overview of PRE-CE Mark Transcatheter Aortic Valve Technologies, Euro PCR, dated May 25, 2010.

Transluminal Aortic Valve Placement, Moazami, Nader, et al., ASAIO Journal, 1996; 42:M381-M385.

Transluminal Catheter Implanted Prosthetic Heart Valves, Andersen, Henning Rud, International Journal of Angiology 7:102-106 (1998). Transluminal implantation of artificial heart valves, Andersen, H. R., et al., European Heart Journal (1992) 13, 704-708.

U.S. Appl. No. 29/375,243, filed Sep. 20, 2010.

U.S. Appl. No. 29/375,260, filed Sep. 20, 2010.

78. Heart repairs without surgery. Minimally invasive procedures aim to correct valve leakage. PubMed ID 15586429.

Buellesfeld et al., Treatment of paravalvular leaks through inverventional techniques; Department of Cardiology, Ben University Hospital 2011.

De Cicco, Giuseppe, et al. "Aortic valve periprosthetic leakage: anatomic observations and surgical results." The Annals of thoracic surgery 79.5 (2005): 1480-1485.

Gössl, Mario, and Charanjit S. Rihal. "Percutaneous treatment of aortic and mitral valve paravalvular regurgitation." Current cardiology reports 15.8 (2013): 1-8.

Muñoz, Daniel Rodriguez, Carla Lázaro Rivera, and José Luis Zamorano Gómez. "Guidance of treatment of perivalvular prosthetic leaks." Current cardiology reports 16.1 (2014): 1-6.

Rohde, I., Masch, J.-M., Theisen-Kunde, D., Marczynski-Bühlow, M., Bombien Quaden, R., Lutter, G. and Brinkmann, R. (2015), Resection of Calcified Aortic Heart Leaflets In Vitro by Q-Switched 2?µm Microsecond Laser Radiation. Journal of Cardiac Surgery, 30: 157-162. doi: 10.1111/jocs.12481.

Swiatkiewicz, Iwona, et al. "Percutaneous closure of mitral perivalvular leak." Kardiologia polska 67.7 (2009): 762.

Transcatheter Umbrella Closure of Valvular and Paravalvular Leaks, Hourihan et al., Journal of the American College of Cardiology, vol. 20, No. 6, pp. 1371-1377, (1992).

Kit Definition, Collins English Dictionary.

* cited by examiner




FIG. 1 (PRIOR ART)







FIG. 2










FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 4E




FIG. 4F






FIG. 5





PARAVALVULAR LEAK OCCLUSION **DEVICE FOR SELF-EXPANDING HEART** VALVES

BACKGROUND OF THE INVENTION

The present disclosure relates in general to heart valve replacement and, in particular, to collapsible prosthetic heart valves. More particularly, the present disclosure relates to devices and methods for positioning and sealing of collapsible prosthetic heart valves.

Prosthetic heart valves that are collapsible to a relatively small circumferential size can be delivered into a patient less invasively than valves that are not collapsible. For example, a 15 collapsible valve may be delivered into a patient via a tubelike delivery apparatus such as a catheter, a trocar, a laparoscopic instrument, or the like. This collapsibility can avoid the need for a more invasive procedure such as full open-chest, open-heart surgery.

Collapsible prosthetic heart valves typically take the form of a valve structure mounted on a stent. There are two types of stents on which the valve structures are ordinarily mounted: a self-expanding stent or a balloon-expandable stent. To place such valves into a delivery apparatus and ultimately into a 25 patient, the valve must first be collapsed or crimped to reduce its circumferential size.

When a collapsed prosthetic valve has reached the desired implant site in the patient (e.g., at or near the annulus of the patient's heart valve that is to be replaced by the prosthetic 30 valve), the prosthetic valve can be deployed or released from the delivery apparatus and re-expanded to full operating size. For balloon-expandable valves, this generally involves releasing the entire valve, and then expanding a balloon positioned within the valve stent. For self-expanding valves, on 35 the other hand, the stent automatically expands as the sheath covering the valve is withdrawn.

SUMMARY OF THE INVENTION

In some embodiments, an occluder device for occluding a gap between a medical device and adjacent body tissue includes an expandable body having a first end and a second end, a fastener coupled to the first end of the body, and an expandable disk coupled to the second end of the body.

In some embodiments, a method for occluding a gap between a prosthetic heart valve and adjacent body tissue includes delivering an occluder into the interior of the heart valve, the occluder having (i) an expandable body, (ii) a fastener coupled to one end of the body, and (iii) an expand- 50 able disk coupled to another end of the body. The occluder is advanced through a cell of the heart valve to the outside of the heart valve. The fastener is coupled to one end of the prosthetic heart valve and the expandable disk is coupled to the

BRIEF DESCRIPTION OF THE DRAWINGS

Various embodiments of the present disclosure are described herein with reference to the drawings, wherein:

FIG. 1 is a side elevational view of a conventional prosthetic heart valve;

FIG. 2 is a highly schematic cross-sectional view taken along line A-A of FIG. 1 and showing the prosthetic heart valve disposed within a native valve annulus;

FIG. 3A is a side view of a conformable occluder in accordance with one embodiment of the present disclosure;

2

FIG. 3B is a side view of the conformable occluder of FIG. 3A after it has been stretched longitudinally:

FIG. 3C is a side view of a conformable occluder having a filler in accordance with another embodiment of the present

FIG. 3D is a side view of a conformable occluder having two fasteners in accordance with another embodiment of the present invention;

FIGS. 4A-F illustrate the steps used to insert a conformable occluder to seal a prosthetic heart valve within a native valve

FIG. 5 is a highly schematic cross-sectional view showing a prosthetic heart valve disposed within a native valve annulus along with a conformable occluder in its fully expanded state;

FIG. 6A is a side view of a conformable occluder in accordance with another embodiment of the present disclosure;

FIGS. **6**B-D are side, top and bottom views showing the use of the conformable occluder of FIG. 6A in vitro;

FIG. 7A is a side view of a conformable occluder in accordance with another embodiment of the present disclosure;

FIGS. 7B-D are side, top and bottom views showing the use of the conformable occluder of FIG. 7A in vitro.

DETAILED DESCRIPTION

Despite the various improvements that have been made to the collapsible prosthetic heart valve delivery process, conventional devices suffer from some shortcomings. For example, with conventional self expanding valves, clinical success of the valve is dependent on accurate deployment and anchoring. Inaccurate deployment and anchoring of the valve increases risks, such as those associated with valve migration, which may cause severe complications and possibly death due to the obstruction of the left ventricular outflow tract. Inaccurate deployment and anchoring may also result in the leakage of blood between the implanted heart valve and the native valve annulus, commonly referred to as paravalvular leakage. This leakage enables blood flow from the aorta back into the left ventricle, reducing cardiac efficiency and putting a greater strain on the heart muscle. Additionally, calcification of the aortic valve may affect performance and the interaction between the implanted valve and the calcified tissue is believed to be relevant to leakage, as will be outlined below.

Moreover, anatomical variations between patients may require removal of a fully deployed heart valve from the patient if it appears that the valve is not functioning properly. Removing a fully deployed heart valve increases the length of the procedure and increases the risk of infection and/or damage to heart tissue. Thus, methods and devices are desirable that would reduce the likelihood of removal. Methods and devices are also desirable that would reduce the likelihood of valve leakage due to gaps formed between the implanted prosthetic heart valve at a position spaced from the one end. 55 heart valve and patient tissue known as paravalvular leaks.

There therefore is a need for further improvements to the devices, systems, and methods for transcatheter delivery and positioning of collapsible prosthetic heart valves. Specifically, there is a need for further improvements to the devices, systems, and methods for accurately implanting a prosthetic heart valve. Among other advantages, the present disclosure may address one or more of these needs.

Various embodiments of the present invention will now be described with reference to the appended drawings. It is to be appreciated that these drawings depict only some embodiments of the invention and are therefore not to be considered limiting of its scope.

As used herein, the term "proximal," when used in connection with a prosthetic heart valve, refers to the end of the heart valve closest to the heart when the heart valve is implanted in a patient, whereas the term "distal," when used in connection with a prosthetic heart valve, refers to the end of the heart salve farthest from the heart when the heart valve is implanted in a patient. When used in connection with devices for delivering a prosthetic heart valve or other medical device into a patient, the terms "trailing" and "leading" are to be taken as relative to the user of the delivery devices. "Trailing" is to be understood as relatively close to the user, and "leading" is to be understood as relatively farther away from the user.

The leak occluders of the present invention may be used in connection with collapsible prosthetic heart valves. FIG. 1 shows one such collapsible stent-supported prosthetic heart valve 100 including a stent 102 and a valve assembly 104 as known in the art. The prosthetic heart valve 100 is designed to replace a native tricuspid valve of a patient, such as a native aortic valve. It should be noted that while the inventions herein are described predominately in connection with their use with a prosthetic aortic valve and a stent having a shape as illustrated in FIG. 1, the valve could be a bicuspid valve, such as the mitral valve, and the stent could have different shapes, such as a flared or conical annulus section, a less-bulbous aortic section, and the like, and a differently shaped transition 25 section.

Prosthetic heart valve 100 will be described in more detail with reference to FIG. 1. Prosthetic heart valve 100 includes expandable stent 102 which may be formed from, for example, a shape memory material, such as the nickel-tita- 30 nium alloy known as "Nitinol" or other suitable metals, and in particular, from those materials that are capable of self-expansion. Stent 102 extends from proximal or annulus end 130 to a distal or aortic end 132, and includes annulus section 140 adjacent proximal end 130, transition section 141 and aortic 35 section 142 adjacent distal end 132. Annulus section 140 has a relatively small cross-section in the expanded condition, while aortic section 142 has a relatively large cross-section in the expanded condition. Preferably, annulus section 140 is in the form of a cylinder having a substantially constant diam- 40 eter along its length. Transition section 141 may taper outwardly from annulus section 140 to aortic section 142. Each of the sections of stent 102 includes a plurality of struts 160 forming cells 162 connected to one another in one or more annular rows around the stent. For example, as shown in FIG. 45 1, annulus section 140 may have two annular rows of complete cells 162 and aortic section 142 and transition section 141 may each have one or more annular rows of partial cells **162**. Cells **162** in a rtic section **142** may be larger than cells 162 in annulus section 140. The larger cells in aortic section 50 142 better enable prosthetic valve 100 to be positioned in the native valve annulus without the stent structure interfering with blood flow to the coronary arteries.

Stent 102 may also include a plurality of commissure features 166 for attaching the commissure between two adjacent 55 leaflets to stent 102. As can be seen in FIG. 1, commissure features 166 may lie at the intersection of four cells 162, two of the cells being adjacent one another in the same annular row, and the other two cells being in different annular rows and lying in end-to-end relationship. Preferably, commissure 60 features 166 are positioned entirely within annulus section 140 or at the juncture of annulus section 140 and transition section 141. Commissure features 166 may include one or more eyelets which facilitate the suturing of the leaflet commissure to the stent.

Stent 102 may include one or more retaining elements 168 at distal end 132 thereof, retaining elements 168 being sized

4

and shaped to cooperate with female retaining structures (not shown) provided on the deployment device. The engagement of retaining elements 168 with the female retaining structures on the deployment device helps maintain prosthetic heart valve 100 in assembled relationship with the deployment device, minimizes longitudinal movement of the prosthetic heart valve relative to the deployment device during unsheathing or resheathing procedures, and helps prevent rotation of the prosthetic heart valve relative to the deployment device as the deployment device is advanced to the target location and the heart valve deployed.

Prosthetic heart valve 100 includes valve assembly 104 preferably positioned in annulus section 140 of the stent 102 and secured to the stent. Valve assembly 104 includes cuff 176 and a plurality of leaflets 178 which collectively function as a one-way valve by coapting with one another. As a prosthetic aortic valve, valve 100 has three leaflets 178, as well as three commissure features 166. However, it will be appreciated that other prosthetic heart valves with which the leak occluders of the present invention may be used may have a greater or lesser number of leaflets 178 and commissure features 166.

Although cuff 176 is shown in FIG. 1 as being disposed on the lumenal or inner surface of annulus section 140, it is contemplated that cuff 176 may be disposed on the ablumenal or outer surface of annulus section 140 or may cover all or part of either or both of the lumenal and ablumenal surfaces. Both cuff 176 and leaflets 178 may be wholly or partly formed of any suitable biological material or polymer such as, for example, polytetrafluoroethylene (PTFE).

Prosthetic heart valve 100 may be used to replace a native aortic valve, a surgical heart valve or a heart valve that has undergone a surgical procedure. The prosthetic heart valve may be delivered to the desired site (e.g., near the native aortic annulus) using any suitable delivery device. During delivery, prosthetic heart valve 100 is disposed inside the delivery device in the collapsed condition. The delivery device may be introduced into a patient using a transfemoral, transapical, transseptal or any other percutaneous approach. Once the delivery device has reached the target site, the user may deploy prosthetic heart valve 100. Upon deployment, prosthetic heart valve 100 expands so that annulus section 140 is in secure engagement within the native aortic annulus. When prosthetic heart valve 100 is properly positioned inside the heart, it works as a one-way valve, allowing blood to flow from the left ventricle of the heart to the aorta, and preventing blood from flowing in the opposite direction.

Problems may be encountered when implanting prosthetic heart valve 100. For example, in certain procedures, collapsible valves may be implanted in a native valve annulus without first resecting the native valve leaflets. The collapsible valves may have critical clinical issues because of the nature of the stenotic leaflets that are left in place. Additionally, patients with uneven calcification, bi-cuspid aortic valve disease, and/or valve insufficiency cannot be treated well, if at all, with the current collapsible valve designs.

The reliance on unevenly calcified leaflets for proper valve placement and seating could lead to several problems, such as paravalvular (also known as perivalvular) leakage (PV leak), which can have severe adverse clinical outcomes. To reduce these adverse events, the optimal valve would anchor adequately and seal without the need for excessive radial force that could harm nearby anatomy and physiology.

FIG. 2 is a highly schematic cross-sectional illustration of prosthetic heart valve 100 disposed within native valve annulus 250. As seen in the figure, annulus section 140 of the stent 102 has a substantially circular cross-section which is disposed within the non-circular native valve annulus 250. At

certain locations around the perimeter of heart valve 100, crescent-shaped gaps 200 form between heart valve 100 and native valve annulus **250**. Blood flowing through these gaps and past valve assembly 104 of prosthetic heart valve 100 can cause regurgitation and other inefficiencies which reduce car- 5 diac performance. Such improper fitment may be due to suboptimal native valve annulus geometry due, for example, to calcification of native valve annulus 250 or to unresected native leaflets.

FIGS. 3A and 3B illustrate one embodiment of conform- 10 able occluder 300 intended to fill irregularities between heart valve 100 and native valve annulus 250 shown in FIG. 2. As will be described in more detail below, conformable occluder 300 allows for superior sealing between the perimeter of heart valve 100 and native valve annulus 250 while affording a low 15 radial outward force. FIG. 3A, shows conformable occluder 300 in a relaxed and expanded configuration while FIG. 3B shows conformable occluder 300 in a stretched and partially elongated configuration. Conformable occluder 300 has a leading end 302 and a trailing end 304, and may generally 20 include body 310, fastener 320, and disk 330.

Body 310 may be a metallic structure that may be longitudinally stretched in the direction of arrows S from a relaxed condition shown in FIG. 3A to a stretched condition shown in FIG. 3B. In the relaxed condition, body 310 may have a 25 cross-section that is greater in size than it is in the stretched condition. Thus, body 310 of conformable occluder 300 may be flexible and capable of contracting in the radial direction when a force is applied thereto to conform to the shape of the annulus in which it will be implanted. Moreover, the ability of 30 body 310 to longitudinally stretch in the direction of arrow S will allow the occluder to be delivered through a small diameter catheter and to be secured between two attachment points as will be seen below with reference to FIGS. 4A-4F.

Occluder 300 may be formed from a tubular section of 35 braided fabric comprising a plurality of braided strands. The strands forming the braid may have a predetermined relative orientation with respect to one another (e.g., a helical braid). The ends of the strands may be located at leading end 302 and trailing end 304 and affixed to prevent unraveling by any 40 suitable means such as solder, braze, weld, coat, glue, clamp, tie, or clamp. Moreover, occluder 300 may comprise a plurality of layers of braided fabric and/or other occluding material (e.g. see filler 345 in FIG. 3C) such that occluder 300 is capable of at least partially inhibiting blood flow therethrough 45 in order to facilitate the formation of thrombus and epithelialization.

Occluder 300 may be formed, for example, of a braided fabric mesh of a shape-memory material, of a super-elastic material, of a bio-compatible polymer, or of another material 50 that is capable of collapsing and expanding. In the embodiments depicted in FIGS. 3A-3C, occluder 300 comprises a braided metal fabric that is both resilient and capable of heat treatment to substantially set a desired preset shape (e.g. the rials which meets these qualifications is shape memory alloys. One example of a shape memory alloy is Nitinol. It is also understood occluder 300 may comprise various materials other than Nitinol that have elastic and/or memory properties, such as spring stainless steel, trade named alloys such 60 as Elgiloy®, Hastelloy®, CoCrNi alloys (e.g., trade name Phynox), MP35N®, CoCrMo alloys, or a mixture of metal and polymer fibers. Depending on the individual material selected, strand diameter, number of strands, and pitch may be altered to achieve the desired properties of occluder 300. 65

As further described below, body 310 may be collapsed during delivery into the patient and re-expanded after delivery 6

to occlude gaps between a prosthetic heart valve and the native valve annulus to one side of the valve. While body 310 is shown in FIG. 3A as having an elliptical longitudinal crosssection in the expanded condition, it will be understood that the body may be constructed with various shapes and/or sizes. For example, body 310 may have a circular, oval, polygonal, square, diamond, triangular or other shape in longitudinal cross-section when expanded. Body 310 may also include two or more segments. Additionally, body 310 may be formed of multiple layers of braid to decrease occlusion time.

Body 310 may be connected to fastener 320 at leading end 302 of conformable occluder 300. Fastener 320 may be formed of a suture, polymeric fiber, metallic filament, such as a flexible stranded stainless steel cable or loop of nitinol wire, or other suitable material, and may be configured to secure conformable occluder 300 to prosthetic heart valve 100 as will be described in greater detail below. Though fastener 320 is shown in FIG. 3A as a loop, it will be understood that a simple hook, clasp or other similar structure capable of grasping, clipping, or hooking conformable occluder 300 to strut 160 of prosthetic heart valve 100 may be used.

Body 310 may further be coupled to disk 330 at trailing end 304 of conformable occluder 300. In the depicted embodiment, body 310 is coupled to disk 330 by a small diameter waist. Disk 330 may be an ovular or spherical body sized to couple conformable occluder 300 to a cell of a prosthetic heart valve. Specifically, disk 330 may be sized larger than cell 162 of stent 102 such that it is incapable of passing through the cell (see FIG. 1). Disk 330 may be formed of the same material as body 310 or from a different material. For example, disk 330 may be formed of a braided nitinol mesh or other shape-memory mesh. It is also contemplated that disk 330 may be constructed from a bio-compatible polymer material. Disk 330 may include a lip having a greater crosssectional dimension than disk 330. Female component 335 connected to disk 330 at trailing edge 335 may be used to couple conformable occluder 300 to a delivery device to position and deliver conformable occluder 300. Female component 335 may include an internally threaded screw attachment, a ring, or any other suitable means for coupling with a delivery device.

In one example, as shown in FIG. 3C, body 310' may be hollow and may be at least partially filled with filler 345 of a fabric or fibers of materials that are intertwined within the mesh of conformable occluder 300' to assist with sealing, occlusion and healing. For example, body 310' may include filler 345 of polyester threads or polyester fabric, as well as any suitable fiber material to increase density and/or promote tissue growth. Filler 345 may also be in the form of a foam material, such as a closed cell sponge. The density of body 310' may be such that it impedes the flow of blood through it. Inclusion of filler 345 in body 310' may speed occlusion time for conformable occluder 300'.

In an alternative embodiment, shown in FIG. 3D, occluder relaxed configuration shown in FIG. 3A). One class of mate- 55 300" has leading end 302 and trailing end 304, and may generally include body 310 extending entirely from leading end 302 to the trailing end 304. As seen in FIG. 3D, occluder 300" includes first fastener 320 at leading end 302. Instead of a disk on the opposite end (see disk 335 in FIGS. 3A-3C), occluder 300" includes second fastener 320' disposed near trailing end 304. In this embodiment, occluder 300" may be coupled to select struts 160 of stent 102 via first and second fasteners 320,320' without the need for disk 335.

> FIGS. 4A-F illustrate the steps used to insert conformable occluder 300 (or conformable occluder 300' or conformable occluder 300") to seal heart valve 100 within native valve annulus 250. As seen in FIG. 4A, heart valve 100 has been

implanted in a patient with annulus portion 140 thereof positioned in native valve annulus 250. Gap G may be formed between heart valve 100 and native valve annulus 250 to one side of heart valve 100.

As an initial step to seal gap G, conformable occluder 300 5 may be disposed within delivery system 400 (FIG. 4A) in a collapsed condition, such as the stretched or elongated configuration shown in FIG. 3B. Delivery system 400 may include outer sheath 410 and inner wire 420 having male component 425. Male component 425 may include a conven- 10 tional screw attachment, a terminal hook or other suitable structure for mating with female component 335. Male component 425 is configured to couple with female component 335 of conformable occluder 300 (elements shown uncoupled in FIG. 4F). Outer sheath 410 is slidable relative to inner wire 420. Delivery system 400 may be inserted into the patient and advanced toward the implanted heart valve 100 in the direction of arrow X. As it reaches heart valve 100, delivery system 400 may be advanced into the heart valve 100 at aortic end 132 and out therefrom through cell 162b in transi- 20 tion section 141 (shown in FIG. 4A). Delivery system 400 may then be further advanced through gap G toward annulus end 140 of implanted heart valve 100, as shown in FIG. 4B. If heart valve 100 or delivery system 400 includes echogenic materials, such materials may be used to guide delivery sys- 25 tem 400 to the appropriate position using the assistance of three-dimensional echocaradiography to visualize heart valve 100 within the patient.

Once delivery system 400 has reached the desired site of sealing (e.g. gap G) as shown in FIG. 4C, outer sheath 410 30 may be retracted slightly in the direction of arrow R (toward the trailing end of delivery system 400) to expose fastener 320 (shown in FIG. 4D). Conformable occluder 300 remains coupled to inner wire 420 at this stage and trailing edge 304 of occluder 300 remains housed by delivery system 400.

Delivery system 400 may be manipulated by gently twisting and/or tilting delivery system 400 to position fastener 320 over the apex of cell 162a at annulus end 130 of heart valve 100. Once fastener 320 has latched onto or been looped around apex of cell 162a, outer sheath 410 may be further retracted in the direction of arrow R to expose body 310 of conformable occluder 300. As outer sheath 410 is further retracted, more of occluder body 310 is exposed and occluder 300 expands within the gap G between heart valve 100 and native valve annulus 250 (FIGS. 4D and 4E). As seen in FIGS. 45 4D-4F, body 310 is positioned parallel to annulus section 140 and transition section 141. In this intermediate stage of deployment, body 310 has expanded to its relaxed state and contacted the walls of native valve annulus 250, and substantially fills gap G.

Outer sheath 410 may then be fully retracted to expose disk 330 and allow it to expand near cell 162b. In the depicted embodiment, disk 330 is located on the interior of heart valve 100, although other in other embodiments, disk 330 is located on the exterior of heart valve 100. In either instance, disk 330 55 is spaced away from valve assembly 104 so as not to impede normal leaflet 178 function. Disk 330 then expands to a size small enough for disk 300 to project partially out of or into cell 162b, but remains too large to pass through that cell. The interference of disk 330 with cell 162b creates a second 60 attachment region for conformable occluder 300. Thus, conformable occluder 300 is stretched between the two attachment regions—the interference between disk 330 and cell 162b and the connection between fastener 320 and cell 162a. Fastener 320 prevents occluder 300 from migrating into the 65 aorta, while disc 330 prevents occluder 300 from migrating back into the heart. Alternatively, in embodiments having two

8

fasteners instead of disk 330 such as that shown in FIG. 3D, first fastener 320 may be coupled to the apex of cell 162a, while second fastener 320' may be likewise coupled over the apex of a cell at the aortic end 132 of stent 100.

Male component 425 may be disconnected from female component 335 by manipulating (e.g., rotating) wire 420. Alternatively, inner wire 420 may comprise a suture tied to female component 335, and the suture may be simply cut to release conformable occluder 300 from delivery system 400. In another example, male and female components may be threaded and delivery system 400 may be twisted relative to occluder 300 to decouple the two from one another. Accordingly, many mating solutions between delivery system 400 and occluder 300 would serve the intended purpose for deployment of occluder 300. FIG. 4F illustrates heart valve 100 in its fully expanded state with conformable occluder 300 fully filling the gap G between heart valve 100 and native valve annulus 250. Delivery system 400 may then be withdrawn in the direction of arrow R and removed from the patient, leaving conformable occluder 300 in place to seal valve 100 within native valve annulus 250.

FIG. 5 is a highly schematic cross-sectional view showing conformable occluder 300 in its relaxed state with body 310 fully radially expanded to fill crescent-shaped gap 200 shown in FIG. 2. The mesh of conformable occluder 300 may be capable of promoting tissue growth between heart valve 100 and native valve annulus 250. For example, conformable occluder 300 may be treated with a biological or chemical agent to promote tissue growth on the conformable occluder, further sealing the heart valve within the native valve annulus. Alternatively, conformable occluder 300 may be sufficiently dense through the use of polyester fibers or polyester fabric to adequately seal the heart valve without the need for major tissue growth throughout gap G. Occluder 300 may also be 35 double-layered and/or may include tighter braiding to more quickly occlude the space between heart valve 100 and native valve annulus 250. When conformable occluder 300 is functioning properly, heart valve 100 will be adequately sealed within native valve annulus 250 so that blood flows through valve assembly 104 and passing through leaflets 108, while limiting or at least reducing blood flow through any gaps formed between heart valve 100 and native valve annulus

FIG. 6A illustrates another embodiment of conformable occluder 600. Conformable occluder 600 extends between leading end 602 and trailing end 604, and may generally include a tubular body 610 and disk 630. Disk 630 includes an enlarged outer rim 632 and is coupled to connector 635 for mating with a delivery system (not shown). As seen in FIG. 6A, reduced diameter neck portion 640 connects body 610 to disk 630. A fastener (not shown) may be attached to joint 650 at leading end 602 to connect occluder 600 to an apex of a cell 162 as described above with reference to FIGS. 4A-4F.

FIGS. 6B-D are side, top and bottom end views illustrating the use of occluder 600. Specifically, FIG. 6B shows a side view of the system while FIG. 6C illustrates a top view (e.g., as seen from aortic end 132 of stent 102) and FIG. 6D illustrates a bottom view (e.g., as seen from annulus end 130 of stent 102). In these figures, container 670 approximates the native valve annulus and stent 102 is disposed therein to simulate a prosthetic heart valve 100. A valve assembly is not shown attached to the stent 102 for the sake of clarity. As seen in FIGS. 6B-D occluder 600 is coupled to stent 102 and shown to fill a gap between stent 102 and the native valve annulus, approximated by the walls of container 670. Specifically, disk 630 is shown disposed within the interior of stent 102 (FIG. 6C) and body 610 is disposed outside of stent 102

(FIG. 6D). Though a fastener is not shown, it will be understood that a fastener may attach to joint 650 and couple leading end 602 of occluder 600 to an apex of a cell at annulus end 130 of stent 102. Occluder 600 may be delivered and positioned in a manner similar to that described above with 5 reference to FIGS. 4A-F.

FIG. 7A illustrates another embodiment of conformable occluder 700. Conformable occluder 700 extends between leading end 702 and trailing end 704, and may generally include a body 710 formed of two body segments 712,712', 10 and disk 730. Though occluder 700 is shown having two segments 712,712' it will be understood that three or more segments may be employed in constructing occluder 700. In some instances, it may be helpful to use multiples segments 712,712' as opposed to a single unitary body to improve 15 occlusion. For example, first segment 712 may expand to a small radius, while a second segment 712' may expand to a larger radius to accommodate a non-uniform native valve annulus and fill multiple gaps at varying longitudinal extents.

Disk 730 includes an enlarged outer rim 732 and is coupled 20 to connector 735 for mating with a delivery system (not shown). As seen in FIG. 7A, two reduced diameter neck portions 740,740' connect body disk 730 to first segment 712 and first segment 712 to second segment 712', respectively. A fastener (not shown) may be attached to joint 750 at leading 25 end 702 to connect occluder 700 to an apex of a cell 162 as described above with reference to FIGS. 4A-4F.

FIGS. 7B-D are side, top and bottom end views illustrating the use of occluder 700 within an approximating container 770 as described above with reference to FIGS. 6B-6D. As 30 seen in FIGS. 7B-D occluder 700 is coupled to stent 102 and shown to fill a gap between stent 102 and the native valve annulus, approximated by the walls of container 770. Specifically, disk 730 is shown disposed within the interior of stent 102 (FIG. 6C) and segments 712,712' are disposed outside of 35 stent 102 (FIG. 6D). Though a fastener is not shown, it will be understood that a fastener may attach to joint 750 to couple leading end 702 of occluder 700 to an apex of a cell at annulus end 130 of stent 102. Occluder 700 may be delivered and positioned in a manner similar to that described above with 40 reference to FIGS. 4A-F.

While the inventions herein have been described for use in connection with heart valve stents having a particular shape, the stent could have different shapes, such as a flared or conical annulus section, a less-bulbous aortic section, and the 45 like, and a differently shaped transition section. Additionally, though conformable occluder 300 has been described in connection with expandable transcatheter aortic valve replacement, it may also be used in connection with surgical valves, sutureless valves and other devices in which it is desirable to 50 create a seal between the periphery of the device and the adjacent body tissue. Additionally, though the deployment of occluder 300 has been described using delivery system 400 that deploys fastener 320 first, followed by body 310 and finally disk 330, it will be understood that, through a different 55 delivery approach, such as, for example, a transapical route, disk 330 may be deployed first, followed by body 310 and then fastener 320.

It will also be understood that while the preceding disclosure has illustrated the use of a single occluder to fill gaps to one side of a prosthetic heart valve, it will be understood that multiple occluders may be deployed around the perimeter of a heart valve. Such occluders may be delivered successively to each gap formed between the prosthetic heart valve and the native valve annulus. Conversely, multiple occluders may be delivered simultaneously using a large single outer sheath having two or more male components or other connectors.

1. A syste comprising:
a prosthet able steep section tion and in the section and occlude and the an occlude and the section that a prosthet are approached.

10

Additionally, multiple occluders may be simultaneously deployed by using multiple delivery systems each having a male component or other connector.

Moreover, although the disclosure herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present disclosure. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present disclosure as defined by the appended claims.

For examples, the occluder may be deployed for use with a prosthetic heart valve having a collapsible and expandable stent forming cells, and a valve assembly disposed in the stent for controlling the flow of blood through the stent. The disk is expandable from a collapsed configuration to a relaxed configuration, the disk in the relaxed configuration having a size larger than the size of at least some of the cells of the stent. The stent may include a plurality of struts and the fastener is coupleable to at least one of the plurality of the struts. The body may include at least one of a metallic mesh or a shapememory material. The body may have an elliptical longitudinal cross-section. The body may include a metal mesh and polyester fiber intertwined with the metal mesh to increase the density of the body. The fastener may include a loop for coupling to the medical device. The disk may include at least one of a metallic mesh or a shape-memory material.

The device may also include a female component or other connected attached to the disk for coupling to a delivery device. The body may include an agent for promoting tissue growth. A system for occluding a gap between a medical device and adjacent body tissue may include the occluder and a delivery system including an outer sheath, an inner wire disposed within and translatable with respect to the outer sheath, and a male component or other connector attached to the inner wire, the male component or other connector being configured to couple the inner wire to the expandable disk of the occluder. The outer sheath may be adapted to house the occluder in a contracted configuration, the medical device is a prosthetic heart valve having a collapsible and expandable stent forming cells and a valve assembly disposed in the stent for controlling the flow of blood through the stent, and the outer sheath is sized to pass through a cell of the expandable stent.

In the methods described above, the fastener may be a loop and the step of coupling the fastener may include positioning the loop around an apex of a cell at the one end of the prosthetic heart valve. The body may have a substantially elliptical longitudinal cross-section in an expanded condition.

It will be appreciated that the various dependent claims and the features set forth therein can be combined in different ways than presented in the initial claims. It will also be appreciated that the features described in connection with individual embodiments may be shared with others of the described embodiments.

The invention claimed is:

1. A system for replacing native valve function, the system comprising:

- a prosthetic heart valve having a collapsible and expandable stent forming cells, the stent having a plurality of sections including an annulus section, a transition section and an aortic section, and a valve assembly disposed in the stent; and
- an occluder device comprising an expandable body having a first end and a second end, a fastener coupled to the first

- end of the body and to a selected strut of the stent at a first position on the annulus section of the stent, and an expandable disk coupled to the second end of the body and passing through a cell of the stent to couple the occluder device to the stent at a second position in a section other than the annulus section.
- 2. The system of claim 1, wherein the disk is expandable from a collapsed configuration to a relaxed configuration.
- 3. The system of claim 2, wherein the disk in the relaxed configuration has a size larger than the size of at least some of the cells of the stent.
- **4**. The system of claim **1**, wherein the stent includes a plurality of struts and the fastener is coupleable to at least one of the plurality of the struts.
- 5. The system of claim 1, wherein the body includes at least 15 one of a metallic mesh or a shape-memory material.
- 6. The system of claim 1, wherein the body has an elliptical longitudinal cross-section.
- 7. The system of claim 1, wherein the body includes a metal mesh and polyester fiber intertwined with the metal mesh.
- 8. The system of claim 1, wherein the disk includes at least one of a metallic mesh or a shape-memory material.
- **9**. The system of claim **1**, further comprising a connector attached to the disk for coupling to a delivery device.
- **10**. The system of claim **1**, wherein the body includes ²⁵ multiple segments, each segment being capable of independent radial expansion from the other segments.
 - 11. The system of claim 1, further comprising:
 - a delivery system including an outer sheath, an inner wire disposed within and translatable with respect to the outer sheath, and a connector attached to the inner wire, the connector being configured to couple the inner wire to the expandable disk of the occluder device.
- 12. The system of claim 11, wherein the outer sheath is adapted to house the occluder device in a contracted configuration, and the outer sheath is sized to pass through a cell of the expandable stent.
- 13. The system of claim 1, wherein the annulus section has a first diameter, the transition section has a second diameter, the first diameter being different than the second diameter, and the expandable disk passes through the cell of the stent in the transition section.
- 14. The system of claim 1, wherein the expandable body is entirely disposed between the fastener and the expandable disk
- **15**. A system for replacing native valve function, the system comprising:
 - a prosthetic heart valve having a collapsible and expandable stent forming cells, and a valve assembly disposed in the stent; and
 - an occluder device comprising an expandable body having a first end and a second end, the first end and the second

12

- end being disposed on opposite ends of the body, a fastener extending in a first direction and coupled to the first end of the body, the fastener capable of latching onto an apex of a cell at a first position, and an expandable disk extending in a second direction, opposite the first direction, and coupled to the second end of the body, the expandable disk passing through a cell of the stent to couple the occluder device to the stent at a second position.
- **16**. A method for occluding a gap between a prosthetic heart valve and adjacent body tissue, the method comprising: providing:
 - (1) a prosthetic heart valve having a collapsible and expandable stent forming cells, the stent having a plurality of sections including an annulus section, a transition section and an aortic section, and a valve assembly disposed in the stent; and
 - (2) an occluder device comprising an expandable body having a first end and a second end, a fastener coupled to the first end of the body and to a selected strut of the stent at a first position on the annulus section of the stent, and an expandable disk coupled to the second end of the body and passing through a cell of the stent to couple the occluder device to the stent at a second position in a section other than the annulus section;
 - delivering an occluder into an interior of the heart valve, the occluder including (i) an expandable body, (ii) a fastener coupled to one end of the body, and (iii) an expandable disk coupled to another end of the body;
 - advancing the occluder through a cell of the prosthetic heart valve to an outside of the heart prosthetic valve;
 - coupling the fastener to one end of the prosthetic heart valve; and
 - coupling the expandable disk to the prosthetic heart valve at a position spaced from the one end.
- 17. The method of claim 16, wherein the fastener is a loop and the step of coupling the fastener includes positioning the loop around an apex of a cell at the one end of the prosthetic heart valve.
- 18. The method of claim 16, wherein the disk in the relaxed configuration has a size larger than the size of at least one of the cells of the stent, and the step of coupling the disk includes disposing the disk on the outside of the at least one cell so that the disk cannot pass therethrough.
- 19. The method of claim 16, wherein delivering the occluder comprises disposing the occluder within a delivery system and advancing the delivery system into an interior of the prosthetic heart valve.
- 20. The method of claim 19, further comprising the step of coupling the expandable disk to an inner wire of the delivery system.

* * * * *